Company ProfilePremium

Financiere de Tubize SA

Company Profile Analysis

Ticker: TUB.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Financiere de Tubize SA - Company showcase

Year Founded & Workforce

1928

3 Employees

Financiere de Tubize SA logo

Financiere de Tubize SA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Financiere de Tubize SA Overview

Financière de Tubize is the reference shareholder of UCB, one of Europe's leading mid-cap biopharmaceutical companies, holding 36.29% of UCB's share capital at 30 June 2026. Founded in 1928, it federates the descendants of UCB founder Emmanuel Janssen together with like-minded long-term investors, and functions as the governance anchor that has kept UCB independent and Belgian-headquartered through successive transformations — from chemicals and films to epilepsy, and now to a global immunology franchise led by BIMZELX. Tubize itself has no operations: its income is UCB's dividend, its costs are a few million euros of overheads, and since May 2025 it carries no bank debt while retaining €350m of committed credit lines as strategic firepower. Its shares have historically traded at a 35–50% discount to the market value of its UCB stake, making Tubize both a governance vehicle and a leveraged-discount proxy for UCB's equity story.


What the company does. Tubize is a pure mono-holding. Its sole investment is its stake in UCB SA (Simply Wall St company profile; Euronext Cofisem profile). Through its representatives on UCB's Board of Directors, Tubize participates in UCB's strategic choices, monitors UCB's performance and seeks to create long-term shareholder value. Its stated mission, as reflected in its communications, is to provide UCB with a stable reference shareholder so that UCB can pursue long-horizon R&D and growth investments.

Company's own description (paraphrased from its public positioning and WEF organisational profile). Tubize presents itself as the reference shareholder of UCB that brings together the family shareholders descending from founder Emmanuel Janssen and investors who share their long-term vision. The 2025 Chair transition statement extended this to supporting a sustainable biopharma ecosystem in Belgium, the UK and other geographies relevant to UCB (Holthof appointment PR, 29 Apr 2025).

Business model. The economic model is extremely simple:

Revenue model mix. 100% investment (dividend) income; 0% product, service, subscription or licensing revenue. Reported "turnover" is effectively nil (StockAnalysis/TipRanks list total revenue of €13.26k for FY2024, i.e., incidental income).

Value chain position. Tubize sits at the top of UCB's ownership chain as controlling-influence holder (not legal control: Tubize has stated in historical Art.74 filings that it is not subject to exclusive or joint control by any party, and it does not hold a majority of UCB).

Customer types / end markets. Tubize has no customers. Its economic exposure is entirely to UCB's end-markets: immunology (psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa), neurology (epilepsy including rare paediatric epilepsies, myasthenia gravis), bone health (osteoporosis via EVENITY, partnered with Amgen) and rare diseases. UCB generates the majority of its revenue in the United States (GuruFocus business description; UCB HY2026 materials).

Independent characterisation. Tubize is best understood as (1) a governance instrument that entrenches family-anchored, long-term ownership of UCB — the "poison-pill-by-shareholding" that makes an unsolicited takeover of UCB practically impossible without Tubize's consent; and (2) a listed security that gives investors leveraged-to-NAV, discounted exposure to UCB. Its cash-flow policy is deliberately conservative: it distributes roughly half of its profit and retains the remainder to keep the UCB stake at or above ~36% and to maintain financial capacity (€350m credit lines) to defend or increase the stake if UCB issues equity for acquisitions.

Strategy

Stated strategy (themes).

  1. Remain UCB's stable reference shareholder at or above ~36%. Historical analyst commentary (Bank Degroof/VFB) records Tubize's stance that it would not fall below its stake threshold and stands ready to buy additional UCB shares if needed.

  2. Professionalise governance and add biopharma expertise: new independent Chair (Apr 2025), Vice-Chair for family relations (Aug 2025), two biopharma directors (Sep 2025).

  3. Maintain financial firepower ("strategic reserves"): €350m committed credit lines renegotiated effective 1 Jan 2026 while carrying zero drawn debt; covenants limit financial debt to 30% of the market value of pledged UCB shares (TUB HY2026 report). Quartr's event summary of Tubize's H2 2025 communication highlights strong long-term TSR and strategic reserves to support UCB's growth while maintaining a 36% stake.

  4. Progressive dividend: Tubize dividend raised every year shown (€0.86 → €0.97 → €1.04 → €1.08 for FY2022–FY2025).

  5. Ecosystem role: support a sustainable biopharma ecosystem in Belgium, the UK and other geographies relevant to UCB (Holthof statement).

Initiatives in last 24 months.

ESG commitments / cost programmes. None separately announced by Tubize.

Medium-term targets. Tubize issues no financial guidance. Its outlook statement is limited to monitoring geopolitical developments and their possible impact on UCB (TUB HY2026). The relevant targets are UCB's: FY2026 revenue growth in the low- to mid-teens % and adjusted EBITDA growth from mid-teens to low-twenties % at CER (upgraded Jul 2026); BIMZELX peak sales ≥€7bn (UCB HY2026 PR). UCB's earlier medium-term ambition was an adjusted EBITDA margin of at least 30%, already exceeded (40.7% in H1 2026).

Products & Services

Holding level. Tubize has no products, brands, platforms or services. Its "product" for investors is a listed share providing discounted exposure to UCB.

Look-through level — UCB portfolio (value driver of Tubize).

Pricing models for UCB products are not publicly disclosed beyond list prices in individual markets; BIMZELX net price is expected to decline in H2 2026 after UCB secured first-line coverage with a major U.S. PBM effective 1 June 2026 (UCB HY2026 call).

Product Portfolio

ProductTherapeutic areaDescription / mechanismKey indicationsStatus / latest datapointSource

BIMZELX (bimekizumab)

Immunology

Humanised monoclonal antibody inhibiting IL-17A and IL-17F

Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa

H1 2026 net sales €1,528m (vs €799m H1 2025, +91%); peak sales guidance raised to ≥€7bn; four head-to-head superiority trials incl. BE BOLD vs risankizumab in PsA; protection to 2037

UCB HY2026 PR; HY2026 call

CIMZIA (certolizumab pegol)

Immunology

Anti-TNF PEGylated Fab'

RA, Crohn's, PsA, axSpA, psoriasis

——

EVENITY (romosozumab)

Bone

Anti-sclerostin antibody, co-developed/commercialised with Amgen

Severe osteoporosis

One of five growth drivers

UCB FY2025 PR

FINTEPLA (fenfluramine)

Neurology (rare epilepsy)

Serotonergic agent, acquired with Zogenix (2022)

Dravet syndrome, Lennox-Gastaut syndrome; positive Ph3 GEMZ in CDKL5 deficiency disorder (Jun 2025)

Growth driver; LOE not before 2033

UCB FY2025 PR; HY2026 call

RYSTIGGO (rozanolixizumab)

Neurology / rare

Anti-FcRn monoclonal antibody

Generalised myasthenia gravis; MOG-AD under study

Growth driver

UCB HY2026 PR

ZILBRYSQ (zilucoplan)

Neurology / rare

Subcutaneous peptide C5 inhibitor

Generalised myasthenia gravis

Growth driver

UCB HY2026 PR

KYGEVVI (doxecitine and doxribtimine)

Rare disease

Nucleoside therapy

Thymidine kinase 2 (TK2) deficiency

Approved in the U.S. (reported in FY2025 PR)

UCB FY2025 PR

BRIVIACT (brivaracetam)

Neurology

SV2A ligand antiepileptic

Partial-onset seizures

Loss of exclusivity in 2026 weighing on H2 2026

UCB HY2026 call summary

VIMPAT (lacosamide)

Neurology

Antiepileptic

Partial-onset seizures

Post-LOE (generics) [recalled]

—

KEPPRA (levetiracetam)

Neurology

Antiepileptic

Epilepsy

Mature/generic [recalled]

—

NAYZILAM / STACCATO alprazolam (pipeline)

Neurology

Rescue therapies for seizure clusters / prolonged seizures

Seizure emergencies

STACCATO alprazolam headline results expected 2026

UCB FY2025 PR

Dapirolizumab pegol (pipeline)

Immunology

Anti-CD40L, partnered with Biogen

Systemic lupus erythematosus

Phase 3

UCB FY2025 PR (Biogen partnership footnote)

Bepranemab (pipeline)

Neurology

Anti-tau antibody

Early Alzheimer's disease

Ph2a: primary endpoint missed, positive secondary endpoints

UCB HY2025 PR

Minzasolmin (pipeline)

Neurology

Alpha-synuclein misfolding inhibitor

Parkinson's disease

Ph2a reported positive results (per FY2025 PR text)

UCB FY2025 PR

Cizutamig (pipeline)

Immunology

T-cell engager from Candid Therapeutics acquisition

Autoimmune diseases

Early data described as promising

UCB HY2026 call

Rezanecel (pipeline)

Neurology

Cell therapy from Neurona acquisition

Drug-resistant epilepsy

Early data described as promising

UCB HY2026 call

Financial Narrative

Accounting note. Tubize's statutory accounts (Belgian GAAP) record UCB at historical acquisition cost; profit therefore reflects only dividends received less costs, not UCB's earnings. Gross profit, EBITDA and "revenue" concepts are not meaningful; they are presented for template completeness. Figures below combine company press releases (net profit, debt) with StockAnalysis/TipRanks aggregator data (balance sheet lines, operating loss), which are consistent with company figures where they overlap.

Income statement

Sources: Net income FY2022–FY2025 from TUB AR2023, AR2024, AR2025 PRs; FY2021 net income, operating income and EPS from TipRanks income statement (FY2025 EPS computed as €93.2m / 44.51m shares). Börse Stuttgart's DPS figures (0.68 / 0.73 / 0.76) correspond to net-of-30%-withholding amounts of the €0.97 / €1.04 / €1.08 gross dividends — a source discrepancy explained by gross vs net.

Margins. Because turnover is nil, gross, operating, EBITDA and net margins are not meaningful (aggregators display nonsensical figures such as a net margin of ~680,000%). The meaningful efficiency ratio is cost-to-income: FY2024 operating costs of ~€2.24m against ~€96m of dividend income (derived) ≈ 2.3%.

Revenue CAGR. Not meaningful; the relevant growth metric is net profit CAGR FY2021–FY2025 of ~2.7% p.a. (83.6 → 93.2), tracking UCB's dividend progression (+2.3–4.3% p.a.) plus incremental UCB shares and lower interest.

Half-year profile. Because the UCB dividend lands in May and costs accrue evenly, H1 profit exceeds full-year profit:

Sources: TUB HY2025 PR; TUB HY2026 PR and report.

Balance sheet

Sources: StockAnalysis balance sheet (Belgian GAAP data); debt figures confirmed by TUB AR2023/AR2024/AR2025 PRs; book value per share computed (equity / 44.51m shares). At 30 Jun 2026, equity was €1,986.3m and the solvency ratio 99.98% (vs 97.49% at end-2025) (TUB HY2026 report via Quartr).

Market-value view (more relevant than book value).

Sources: TUB ARs/HY PRs (stake %); shares held derived from stake × 194,505,658 UCB shares, cross-checked to Art.74 notifications (70,502,554 shares at 31 Jul 2024; 70,562,935 at 31 Jul 2025); market cap from TUB HY2026 report.

Cash flow

Sources: TUB AR2024/AR2025 PRs (debt movements, UCB purchases, dividends). A formal cash-flow statement is not published in the retrieved materials; FY2023 UCB share purchases (1,043,881 shares) were material but the euro amount is not disclosed in retrieved documents. Free cash flow ≈ dividends received − costs − interest ≈ net income.

Capital allocation in 2025 (illustrative waterfall, EUR M): UCB dividend received 98.1 → less dividend paid 46.3 → less UCB shares bought 4.4 → less overheads/interest ~3 → remainder applied to repaying 41.3 of debt (TUB AR2025 PR, HY2025 PR).

Ratios

Computations by analyst–6.2 data (ROE and ROA on average balances; payout = DPS × 44.51m / net income). ROIC, current ratio, interest coverage, net debt/EBITDA, asset turnover and cash-conversion cycle are not meaningful for a debt-free mono-holding with no operations; interest coverage was high throughout (H1 2025 interest €0.7m vs ~€96m profit).

Trend commentary. The five-year record shows three phases. First, deleveraging (2016–2021): debt fell from €241m to €20m as Tubize retained most of the UCB dividend. Second, re-leveraging to raise the stake (2022–2023): Tubize took debt back up to €79.2m to buy over 1.6m UCB shares and lift its stake from below 35.7% to 36.24% — a deliberate move ahead of UCB's BIMZELX-driven re-rating, which in hindsight created substantial value. Third, a debt-free steady state (2024–2026): debt was repaid in May 2025, top-ups of the stake have shrunk to symbolic amounts (24,487 shares in 2025; 15,783 in H1 2026 at €256.4 average), and the dividend to Tubize shareholders now grows in line with UCB's (+3.8% in 2026). The book-value ROE of ~5% is structurally understated because UCB is carried at cost; on market value, Tubize's earnings yield on its stake is under 1%.

Look-through earnings (analyst construct). Applying Tubize's 36.29% stake to UCB's FY2025 Core EPS of €9.99 (UCB FY2025 PR) gives look-through core earnings of ~€705m (70.57m shares × €9.99), or ~€15.8 per Tubize share — versus reported EPS of €2.09. On H1 2026 Core EPS of €6.84, the half-year look-through figure is ~€483m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRoleOwnership

Financière de Tubize SA

Listed mono-holding

Free float plus Janssen-family concert

UCB SA

Listed operating biopharma group

36.29% held by Tubize (30 Jun 2026)

Subsidiaries of Tubize

None identified

—

Per-Share Data and Revenue by Segment

MetricFY2021FY2022FY2023FY2024FY2025H1 2026

UCB gross DPS received in the year (EUR)

1.271.301.331.361.391.45

UCB dividend received (EUR Mn)

————98.1102.3

Derived UCB dividend received (EUR Mn, DPS × shares held, analyst estimate)

——929698.1102.3

YoY growth of dividend received (%)

—————4.3

Share of total income (%)

100100100100100100

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue / turnover (EUR Mn)

00.0100.010

Dividend income from UCB (EUR Mn)

————98.1

Operating income (EUR Mn)

-1.54-1.82-2.14-2.24—

Pre-tax income (EUR Mn)

83.685.288.290.193.2

Net income (EUR Mn)

83.685.288.290.193.2

EPS basic and diluted (EUR)

1.881.911.982.022.09

Gross dividend per share declared for the year (EUR)

—0.860.971.041.08

Net income growth (%)

—1.93.52.23.5

Dividends & Capital Returns

MetricH1 2024H1 2025H1 2026

Half-year net profit (EUR Mn)

92.995.6100.8

UCB dividend received (EUR Mn)

—98.1102.3

Dividend paid to Tubize shareholders (EUR Mn)

—46.348.1

Interest expense (EUR K)

—7190

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR Mn)

1,7591,8391,9201,9301,934

Financial fixed assets — UCB stake at cost (EUR Mn)

1,7431,8381,9201,9281,933

Cash and short-term investments (EUR Mn)

15.91.070.571.431.27

Total bank debt — all short-term drawings (EUR Mn)

2047.879.241.30

Long-term debt (EUR Mn)

00000

Net debt (EUR Mn; negative = net cash)

4.146.778.639.9-1.3

Shareholders' equity (EUR Mn)

1,7051,7521,7971,8401,886

Goodwill and intangibles (EUR Mn)

00000

Book value per share (EUR)

38.339.440.441.342.4

Share Count (M) and Margin Analysis (%)

MetricFY2023FY2024FY2025H1 2026

UCB shares held (M)

70.4970.5570.5770.58

Stake in UCB (%)

36.2436.2736.2836.29

Tubize market capitalisation (EUR Mn)

——9,30010,282

Dividends & Capital Returns (Annual)

MetricFY2021FY2022FY2023FY2024FY2025

Capex (EUR Mn)

00000

Investment in UCB shares (EUR Mn)

————4.4

Dividends paid to shareholders (EUR Mn)

————46.3

Net debt repayment (EUR Mn)

———37.941.3

Buybacks (EUR Mn)

———00

Returns & Leverage Ratios (%)

RatioFY2021FY2022FY2023FY2024FY2025

ROE on book equity (%)

—4.95.04.95.0

ROA (%)

—4.74.74.74.8

Debt / equity (%)

1.22.74.42.20

Net debt / market value of UCB stake (%)

————0

Payout ratio (dividend declared / net income, %)

—45495152

Solvency ratio (equity / total assets, %)

96.995.393.695.397.5

Revenue by Region (%)

RegionFY2023FY2024FY2025

Belgium — UCB dividend share of Tubize income (%)

100100100

All other regions (%)

000

Revenue by Region and Region Margins & Growth (%)

MetricFY2023FY2024FY2025

UCB total revenue (EUR Mn)

5,2516,1527,741

UCB total revenue growth (%)

-51726

Share Price and Market Valuation

MetricFY2023FY2024FY2025H1 2026

Period-end share price (EUR)

——209231

Market capitalisation (EUR Mn)

——9,30010,282

Net profit (EUR Mn)

88.290.193.2100.8

Gross DPS for the year (EUR)

0.971.041.08—

Valuation Multiples

MultipleTubize (reported)Tubize (look-through, analyst)UCB

P/E

~89–110x on statutory EPS (€2.09)

~11.7x (market cap ~€8.3bn / look-through core earnings ~€705m)

~18–20x trailing (GuruFocus, Aug 2026)

P/B

~4.4–4.8x on book (cost basis)

~0.53x on NAV (≈47% discount)

~3.4–3.6x

EV/EBITDA

n/m

n/m

~12.9x EV/EBITDA (Simply Wall St, date unspecified)

EV/Sales

n/m

n/m

~5x

Dividend yield

~0.5%

—

~0.6–0.7%

Source Details

SourceViewTarget

Stockopedia consensus

Hold

€230.50

KBC Securities (Livio Luyten)

Downgraded Buy → Accumulate (Aug 2025)

—

TipRanks

"Overvalued" per its model

—

Per-Share Data and Margin Analysis (%)

MetricFY2017FY2018FY2022FY2023FY2024FY2025

Gross dividend per share (EUR)

0.540.560.860.971.041.08

YoY growth (%)

—3.7—12.87.23.85

Analyst Conclusions

Management guidance. Tubize gives no quantitative guidance; it states that it remains attentive to geopolitical developments and their potential impact on UCB and on its own results, with no significant post-balance-sheet events at 30 Jun 2026 (TUB HY2026).

Consensus / underlying expectations. UCB guides FY2026 revenue growth in the low- to mid-teens % and adjusted EBITDA growth in the mid-teens to low-twenties % at CER (UCB HY2026 PR). UCB's dividend has grown 2–4% p.a.; given UCB's earnings step-change (Core EPS €9.99 in FY2025, €6.84 in H1 2026 alone), the board has latitude for faster dividend growth, which would flow directly into Tubize's profit.

Bull case

  1. UCB compounding: BIMZELX peak ≥€7bn and EBITDA margin above 40% imply sustained double-digit earnings growth, lifting Tubize's NAV mechanically.

  2. Discount mean-reversion: at ~47% vs a long-run 36–42% band, a return to the average would add ~15–20% to Tubize independent of UCB.

  3. Free optionality: zero debt plus €350m of lines lets Tubize buy UCB shares after sell-offs (as it did in 2023), accreting NAV per share.

Bear case

  1. H2 2026 headwinds: BIMZELX net price erosion, Briviact LOE and higher R&D could cap UCB's share price, as the Jul 2026 reaction showed.

  2. Structural discount: single-asset concentration, a ~0.5% yield and family control may keep the discount at or above 50%, as in 2024.

  3. Dilution / capital calls: an equity-funded UCB mega-deal would force Tubize to draw debt or accept dilution below 36%.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict. Financière de Tubize is one of Europe's cleanest holding-company structures: a single asset, no debt, negligible overheads and a stable family anchor that has accompanied UCB for nearly a century. The financial statements are deliberately uninformative — €93.2m of statutory profit in FY2025 says little about a company whose 36.29% stake in UCB carries look-through core earnings of roughly €700m and a market value in the region of €15–16bn. The investment case therefore reduces to two variables: UCB's equity value and the discount at which Tubize trades against it.

On the first, UCB has rarely been in better shape. Revenue grew 26% in FY2025, adjusted EBITDA nearly doubled, H1 2026 margins exceeded 40%, BIMZELX's peak-sales ambition was raised to at least €7bn, and the patent runway extends into the 2030s. The near-term debate — U.S. net pricing after broader BIMZELX access, Briviact generics, and a reinvestment cycle in R&D and M&A — is real, and the market's reaction to UCB's half-year results shows sentiment is now sensitive to execution rather than discovery.

On the second, the discount of roughly 47% computed at early-autumn 2026 prices sits wide of Tubize's long-term averages. The new governance — an independent Chair, two former big-pharma executives, a Vice-Chair dedicated to family relations — signals a more professional holding, but there is no explicit discount-control policy, buyback usage, or payout step-up yet. Without such actions, the discount is more likely to oscillate than close.

The resulting verdict is a constructive but conditional one: Tubize is an efficient, lower-beta, cheaper way to own UCB's growth. The most important monitorables are UCB's FY2026 dividend decision, any Tubize capital-return initiative, and whether Tubize deploys its €350m lines if UCB's shares weaken further.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundCompensation

Eric Nys (via ENRE SRL)

CEO / Managing Director ("Directeur"); also Head of Investor Relations

Signs Art.74 notifications for Tubize (e.g., 25 Aug 2025); contact for AGM matters since at least 2023

Not disclosed in retrieved materials; total remuneration covered in annual remuneration report

Anne Keup

Deputy General Manager

Listed by Euronext/Cofisem (Mar 2025)

—

Anne Sophie Pijcke

Director / company contact (historical)

Contact on 2017–2018 annual reports; still listed as Euronext contact

—

“—” = not publicly disclosed.

Board of Directors

NameRoleSinceProfile

Bruno Holthof

Chair (independent)

Chair from 25 Apr 2025 (previously independent director)

—

Cyril Janssen

Vice-Chair (family)

Vice-Chair from 1 Aug 2025

Janssen family; co-controls Financière Eric Janssen; manages family-shareholder relations; UCB board member [UCB role recalled]

Evelyn du Monceau

Director (family)

1982

Former Chair of UCB; former director of Solvay and Solvac; member of the Belgian Corporate Governance Committee; holds ~11.26% of Tubize (MarketScreener, 31 Dec 2025)

Iris Löw-Friedrich

Director

23 Sep 2025

MD, PhD; former Head of Development and Chief Medical Officer of UCB; board member of Fresenius SE, Sobi AB, Evotec SE

Carinne Brouillon

Director

23 Sep 2025

30+ years in healthcare including 21 years at Johnson & Johnson; Board of Managing Directors of Boehringer Ingelheim (Human Pharma) Jan 2020–Sep 2024; Supervisory Board of Munich Re since Apr 2021

Gaëtan Hannecart

Former Chair

Left board 25 Apr 2025

Oversaw generational transition and build-out of management team

Major Shareholders

HolderStake (%)Date / source

Financière Eric Janssen SPRL (jointly controlled by Eric and Cyril Janssen)

23.60

FSMA notification 30 Dec 2015 (denominator 44,548,598)

Evelyn du Monceau (incl. Altaï Invest)

11.26

MarketScreener, 31 Dec 2025

Baron Daniel Janssen (estate/heirs)

13.19

FSMA, Mar 2013 (historical; may have changed)

Barnfin SA (van Rijckevorsel)

8.64

FSMA, Mar 2013 (historical)

Concert total (2013 notification)

51.98

FSMA

Free float (residual, approx.)

~48

Derived

Financière de Tubize

36

UCB shareholders page, Oct 2025

FMR (Fidelity)

7.5

Same

BlackRock

6

Same

UCB treasury shares

2

Same

Other institutions

32

Same

Retail

11

Same

Competitive Landscape

Key Competitors

PeerTypeRelevance to Tubize

UCB SA (direct)

Underlying operating company

Investors choose between UCB direct (no discount, full liquidity) and Tubize (discount, lower liquidity, family governance)

Solvac SA

Belgian mono-holding (Solvay family)

Closest structural analogue: family-controlled listed holding over a single Belgian listed group

Groupe Bruxelles Lambert (GBL)

Belgian diversified holding

Benchmark Belgian holding discount

Sofina SA

Belgian diversified holding (incl. healthcare/life sciences)

Long-term family investor

Ackermans & van Haaren

Belgian diversified holding

Benchmark

Brederode SA

Belgian/Luxembourg holding

Benchmark

Gimv

Belgian listed private equity (life sciences exposure)

Healthcare investment alternative

Quest for Growth

Belgian listed investment company

Healthcare/tech small-cap exposure

Investor AB

Swedish holding (Wallenberg)

Pan-European holding benchmark, owns stakes in pharma (AstraZeneca)

Exor NV

Agnelli family holding

Family-holding benchmark

Novo Holdings / Lundbeckfonden (unlisted)

Foundation owners of Novo Nordisk / Lundbeck

Governance analogues (stable controlling owners of pharma)

Competitor Detail

UCB franchiseMain competitorsCompeting products

BIMZELX (IL-17A/F)

AbbVie; Johnson & Johnson; Novartis; Eli Lilly; Amgen

Skyrizi, Rinvoq; Tremfya, Stelara; Cosentyx; Taltz; Otezla

CIMZIA (anti-TNF)

AbbVie; J&J; Amgen; biosimilar makers

Humira and biosimilars; Simponi, Remicade; Enbrel

RYSTIGGO / ZILBRYSQ (gMG)

argenx; AstraZeneca/Alexion; J&J

Vyvgart; Ultomiris, Soliris; nipocalimab

FINTEPLA (rare epilepsy)

Jazz Pharmaceuticals; Takeda; others

Epidiolex; soticlestat (pipeline)

Epilepsy (Briviact/Vimpat/Keppra)

Generic manufacturers; SK Life Science; Eisai

Generics; Xcopri; Fycompa

EVENITY (osteoporosis)

Amgen (Prolia); Eli Lilly; Radius

Prolia/biosimilars; Forteo; Tymlos

Peer Comparison FY2025

MetricTubizeUCBSolvacGBL

Structure

Mono-holding

Operating biopharma

Mono-holding

Diversified holding

Underlying asset concentration

1 asset (UCB 36.29%)

—

1 asset (Solvay)

Multi-asset

Latest revenue / income

€93.2m net profit FY2025

€7,741m revenue FY2025

——

Growth

+3.5% net profit FY2025

+26% revenue FY2025

——

Margin

n/m

Adj. EBITDA 34.1% FY2025; 40.7% H1 2026

n/m

n/m

R&D intensity

0%—0%0%

Net debt

Nil (net cash €1.3m YE2025)

———

Company Snapshot

3

Employees

1928

Founded

SWOT Analysis

Strengths

  • Debt-free since May 2025 after carrying €241m at end-2016 (TUB AR2017, AR2025).
  • Steadily rising income: UCB dividend received rose from €98.1m (2025) to €102.3m (2026) (TUB HY PRs).
  • Ultra-low cost base: operating loss of only €2.24m in FY2024 against ~€96m of income (Euronext/Cofisem).
  • Strategic firepower: €350m committed credit lines available but undrawn (AGM notice, Mar 2026).
  • Underlying asset in strong growth: UCB FY2025 revenue +26%, adj. EBITDA +79%, Core EPS €9.99 (UCB FY2025 PR).
  • Stable family anchor: Janssen concert held 51.98% of Tubize (FSMA 2013), with Evelyn du Monceau still at 11.26% (2025).
  • Strengthened board: two former big-pharma executives added Sep 2025.

Weaknesses

  • Single-asset concentration: 100% of income from UCB.
  • Persistent wide discount (>50% in May 2024; ~47% computed Oct 2026).
  • Low cash return: dividend €1.08 vs share price ~€185–231 (yield ~0.5%).
  • Book accounting at cost hides value: book equity €1.9bn vs stake market value ~€15–16bn.
  • Limited disclosure: no consolidated/look-through reporting, minimal IR materials.
  • Thin liquidity and small free float relative to market cap.

Opportunities

  • BIMZELX peak sales guidance raised to ≥€7bn (UCB HY2026).
  • UCB margin expansion (adj. EBITDA margin 40.7% H1 2026 vs 29.6% H1 2025) supports faster UCB dividend growth.
  • Debt-free balance sheet allows more aggressive UCB buying on weakness (e.g., after the Jul 2026 sell-off).
  • Discount-narrowing tools: share buybacks (5-year authorisation from Apr 2025), higher payout, improved IR.
  • Pipeline catalysts (STACCATO alprazolam readout 2026; multiple Ph3 programmes).
  • Index inclusion and passive ownership (EURO STOXX Small, STOXX 600 Health Care ETFs).

Threats

  • UCB-specific setbacks: BIMZELX U.S. net price pressure from H2 2026; Briviact generics in 2026 (UCB HY2026 call).
  • U.S. drug-pricing policy (IRA, MFN-type measures) given UCB's majority-U.S. revenue.
  • Dilution risk if UCB funds large M&A with equity (Tubize must subscribe or fall below 36%).
  • Pipeline failures (e.g., bepranemab missed primary endpoint in Ph2a).
  • Geopolitical/tariff risks to UCB supply chain flagged in the TUB HY2026 report.
  • Tax/regulatory changes on Belgian holding structures or dividend withholding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
25 Apr 2025Tubize AGM/EGM: FY2024 accounts approved; new share buyback and anti-takeover authorisationsGovernance tools renewed
25 Apr 2025Hannecart leaves; Holthof elected ChairLeadership transition to independent chair
30 Apr–5 May 2025FY2024 dividend €1.04 gross (ex 30 Apr, paid 5 May)+7.2%
Early May 2025UCB pays €1.39 dividend; Tubize receives €98.1mAnnual income event
May 2025Tubize repays all bank debt (€41.3m)Debt-free
Jun 2025UCB: positive Ph3 GEMZ (fenfluramine, CDKL5)FINTEPLA label expansion
31 Jul 2025UCB HY2025: revenue €3,487m (+25%), adj. EBITDA €1,033m (29.6%); FY2025 guidance raised to ≥€7bn revenueValue driver up
1 Aug 2025Cyril Janssen appointed Tubize Vice-ChairFamily-relations governance
2 Aug 2025Tubize HY2025: profit €95.6m (+2.8%)Steady
Aug 2025KBC Securities downgrades Tubize from Buy to Accumulate, while remaining positive long termSell-side sentiment
25 Aug 2025Art.74 notification: 70,562,935 UCB shares (36.28%) at 31 Jul 2025Annual stake disclosure
23 Sep 2025Tubize EGM appoints Löw-Friedrich and BrouillonBiopharma expertise added
Late 2025UCB upgrades 2025 guidance: revenue >€7.6bn, adj. EBITDA margin >31% excluding one-off brand salePositive
31 Dec 2025Tubize market cap €9.30bnYear-end marker
1 Jan 2026Tubize credit lines renegotiated (€350m unchanged)Firepower maintained
26 Feb 2026UCB FY2025: revenue €7,741m (+26%), net sales €7.39bn (+32%), adj. EBITDA €2,636m (+79%), Core EPS €9.99, DPS €1.45 proposedStrong year
21 Mar 2026Tubize FY2025 annual report: profit €93.2m (+3.5%); DPS €1.08 proposedResults
25 Mar 2026AGM convening notice; board renewal/appointment items on agendaGovernance
24 Apr 2026Tubize AGM approves FY2025 accounts—
6 May 2026UCB pays €1.45 dividend (coupon 29); Tubize receives €102.3m+4.3%
7–11 May 2026Tubize FY2025 dividend €1.08 (ex 7 May, paid 11 May)+3.85%
1 Jun 2026BIMZELX gains first-line coverage with a major U.S. PBMVolume up, net price down
30 Jun 2026Tubize stake 36.29%; equity €1,986.3m; market cap €10.28bnHalf-year marker
30 Jul 2026UCB HY2026: revenue €4,270m (+22%), BIMZELX €1,528m, adj. EBITDA €1.74bn (40.7%), Core EPS €6.84; FY2026 guidance upgraded; BIMZELX peak ≥€7bnStrong but H2 headwinds flagged
30 Jul 2026UCB shares fall ~5–8% on the day (release-day prices around €236–241 vs ~€221 afterward) on H2 caution (Briviact LOE, BIMZELX pricing, higher R&D)Read-across to Tubize
1 Aug 2026Tubize HY2026: profit €100.8m (+5.4%); 15,783 UCB shares bought at €256.4Results
Jul–Sep 2026Tubize shares drift from ~€209 (22 Jul) to ~€185 (early Sep) on Stuttgart quotesDe-rating with UCB
2026UCB announces acquisitions of Candid Therapeutics, Neurona, IMIDomics; in-licensing from AntengenePipeline build; potential capital needs

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: UCB dividend received rose from EUR 98.1 Mn in FY2025 to EUR 102.3 Mn in H1 2026.
Financiere de Tubize SA — Revenue by Segment
Series (EUR Mn)FY2023FY2024FY2025H1 2026
UCB dividend received——98.1102.3
UCB dividend received (EUR M, DPS × shares held, analyst estimate)929698.1102.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Financière de Tubize — Annual report 2025 press release (santelog/Nasdaq: VFB NL PDF) — 21 Mar 2026 — FY2025 profit, debt repayment, UCB purchases, DPS, address
  2. Financière de Tubize — Half-year report 2026 PR and full NL report (VFB) — 1 Aug 2026 — H1 2026 profit, UCB dividend, stake, market cap, credit covenants, risks
  3. Quartr — Tubize H1 2026 event summary — 3 Aug 2026 — Equity, solvency ratio, market cap
  4. Financière de Tubize — Half-year report 2025 PR — 2 Aug 2025 — H1 2025 data, debt nil
  5. Financière de Tubize — Annual reports 2017, 2018, 2023, 2024 PRs — 2018–2025 — Historical profits, debt, dividends
  6. Financière de Tubize — PRs on Chair appointment and new directors (GlobeNewswire) — 29 Apr 2025; 24 Sep 2025 — Governance
  7. Financière de Tubize — AGM convening notices 2023, 2025, 2026 — 2023–2026 — Authorisations, credit lines
  8. UCB — Art.74 notifications and shareholders page — 2007–2025 — Stake history, UCB dividends, UCB shareholders
  9. UCB filing 081031 (concert declarations) — Oct 2008 — Concert agreements
  10. FSMA shareholding register for Tubize — Accessed 2026 — Tubize shareholders
  11. UCB — FY2025 results PR: HY2025 report · HY2026 PR; guidance-upgrade PR · IAR 2025 — 2025–2026 — Look-through operating data
  12. GuruFocus / Investing.com HY2026 UCB call summaries — Jul–Aug 2026 — UCB guidance, LOE dates, price reaction
  13. StockAnalysis: TipRanks · Stockopedia · Börse Stuttgart · Simply Wall St; justETF · Lightyear; rendementbourse — 2025–2026 — Balance-sheet history, price and valuation data (aggregators — secondary)
  14. Bolero / KBC Securities blogs: VFB / Degroof analysis · Ariva / finanznachrichten — 2020–2026 — Discount history and sell-side views
  15. MarketScreener insider profile (Evelyn du Monceau) — 2026 — Board member holding

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.